Fermenta Biotech Ltd
P&L
Quarterly Consolidated
vs Q4 FY25
Fermenta Biotech Ltd. Reports 39% Revenue Surge in FY25, Achieves Robust Financial Turnaround
12 Aug 2025 · 12 Aug 2025, 02:47 pm
Summary
Fermenta Biotech Ltd. has reported a 39% surge in revenue for FY25, amounting to 481 crore. The company has restored profitability with an EBITDA of 3122 crore and a net profit of 376 crore, compared to a net loss in the previous year. The turnaround spans the company's financials, operations, and strategy. Recent highlights include manufacturing and technology breakthroughs, human nutrition innovations, and global recognition.
Key Highlights
- 1
39% surge in revenue in FY25
- 2
Restored profitability with EBITDA of 3122 crore and net profit of 376 crore
- 3
Manufacturing and technology breakthroughs
- 4
Human nutrition innovations
- 5
Global recognition
- 6
Completed validation batches for spray dried variant of Vitamin D3
- 7
Commissioned 100,000 lU/g powder for human nutrition - Vitamin D3 100 SD
- 8
Began commercial scale production of Vitamin K1 using proprietary plant-source technology
- 9
Acquired 52% stake in AGD Nutrition
- 10
Launched spray dried technology from wellness Vitamin D3 Feed Grade R&D to VITADEE™ Green 500 by Fermenta manufacturing
- 11
Received approvals from GAIN and WFP, EU GMP and US EDA for the Dahej facility
Management Comments
Not specified
Strategic Realignment Delivers Results Refocused strategy on execution, efficiency, and innovation after navigating significant post- pandemic headwinds over the past two years Robust Financial Turnaround Consolidated revenue surged to 481 crore, up 39% from 347 crore in FY24 Restored profitability with EBITDA of 3122 crore and net profit of 376 crore versus prior year net loss Strong Foundation for Future Growth Enhanced balance sheet strength and renewed confidence position Fermenta for continued momentum in FY26 Turnaround spans Fermenta’s financials, operations, strategy
Informational and educational content only. Not investment advice.